• CG Oncology, Inc. reported past full-year 2025 results, with revenue rising to US$4.04 million from US$1.14 million and net loss widening to US$161 million from US$88.04 million, alongside confirmation that its leadership presented at the TD Cowen 46th Annual Health Care Conference earlier this month.
• The combination of higher revenue with a larger loss highlights the company’s ongoing investment in its business model and cost structure, which investors may weigh against its early-stage commercial progress.
• With recent share price gains, we’ll examine how rising revenue but a larger full-year loss shapes CG Oncology’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is CG Oncology's Investment Narrative?

To own CG Oncology here, you really have to believe that cretostimogene’s Phase 3 programs in non-muscle invasive bladder cancer can ultimately justify years of heavy spending. The latest full-year 2025 results reinforce that trade-off: revenue has started to build at US$4.04 million, but the net loss widened to US$161 million and loss per share increased, underscoring how dependent the story remains on successful trial readouts and eventual regulatory decisions rather than current commercial traction. With topline PIVOT-006 data still a key near-term catalyst, this bigger loss profile sharpens the focus on cash burn, funding needs and execution risk, even as the share price has moved higher in recent months. The TD Cowen conference appearance mainly supports visibility and communication, but does not materially change these core risks and catalysts.

However, one risk around CG Oncology’s rising losses and future funding needs is easy to overlook. CG Oncology's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

The Simply Wall St Community currently contributes 1 fair value estimate for CG Oncology, clustering around US$296.76 per share, highlighting how far some retail investors see upside. Set against widening annual losses of US$161 million and reliance on upcoming Phase 3 bladder cancer data, these views underline how differently market participants can frame risk and reward in this stock. Readers may want to compare these community estimates with their own assessment of trial, regulatory and financing uncertainty.

Explore another fair value estimate on CG Oncology - why the stock might be worth just $296.76!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CG Oncology research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CG Oncology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CG Oncology's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.